# PRAMEF4

## Overview
PRAMEF4 is a gene that encodes the protein PRAME family member 4, which is part of the PRAME (Preferentially Expressed Antigen in Melanoma) gene family. This family is characterized by its involvement in immune response modulation and cancer biology. The PRAMEF4 protein is implicated in various biological processes, although its specific functions remain to be fully elucidated. It is notably overexpressed in certain pathological conditions, such as facioscapulohumeral muscular dystrophy (FSHD) and various cancers, where it may serve as a biomarker or contribute to disease pathogenesis (Wong2023Validation; Tasca2012Different). The PRAME family, including PRAMEF4, is recognized for its role in triggering immune responses in tumors, such as melanoma, and is often used as a prognostic marker in oncology (Kern2021The; Dhivyadharshini2020Decoding). Further research is needed to clarify the specific biological roles and clinical implications of PRAMEF4.

## Clinical Significance
PRAMEF4, a member of the PRAME gene family, has been implicated in various diseases due to alterations in its expression levels. In facioscapulohumeral muscular dystrophy (FSHD), PRAMEF4 is part of a subset of DUX4-regulated genes that can distinguish mild-to-moderate FSHD from control muscle, indicating its potential role as a biomarker for this condition (Wong2023Validation). The gene's expression is notably altered in FSHD muscle tissues, where it is overexpressed in certain samples, suggesting a link to the disease's pathogenesis (Tasca2012Different).

PRAMEF4 is also part of the broader PRAME gene family, which is known for its involvement in cancer biology. While specific mutations in PRAMEF4 have not been detailed, the PRAME family is associated with various tumors and is known to trigger immune responses in cancers such as melanoma (Dhivyadharshini2020Decoding). The expression of PRAME genes, including PRAMEF4, is abundant in many malignant tumors, serving as prognostic markers for cancer patients (Kern2021The). This suggests that alterations in PRAMEF4 expression could contribute to tumor progression and immune evasion, although specific clinical outcomes related to PRAMEF4 require further investigation.


## References


1. (Wong2023Validation) Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial design. This article has 0 citations.

[2. (Tasca2012Different) Giorgio Tasca, Mario Pescatori, Mauro Monforte, Massimiliano Mirabella, Elisabetta Iannaccone, Roberto Frusciante, Tiziana Cubeddu, Francesco Laschena, Pierfrancesco Ottaviani, and Enzo Ricci. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS ONE, 7(6):e38779, June 2012. URL: http://dx.doi.org/10.1371/journal.pone.0038779, doi:10.1371/journal.pone.0038779. This article has 100 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0038779)

[3. (Kern2021The) Chandlar H Kern, Mingyao Yang, and Wan-Sheng Liu. The prame family of cancer testis antigens is essential for germline development and gametogenesis. Biology of Reproduction, 105(2):290–304, April 2021. URL: http://dx.doi.org/10.1093/biolre/ioab074, doi:10.1093/biolre/ioab074. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/biolre/ioab074)

[4. (Dhivyadharshini2020Decoding) J. Dhivyadharshini, A. S. Smiline Girija, A. Paramasivam, and J. Vijayashree Priyadharsini. Decoding the genetic alterations in prame gene family and its association with head and neck squamous cell carcinoma. Journal of Pharmaceutical Research International, pages 93–102, August 2020. URL: http://dx.doi.org/10.9734/jpri/2020/v32i2030733, doi:10.9734/jpri/2020/v32i2030733. This article has 0 citations.](https://doi.org/10.9734/jpri/2020/v32i2030733)